Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Dehm

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|April 19, 2024
Androgen receptor and estrogen receptor variants in prostate and breast cancersJosé C Valentín López, Carol A Lange, Scott M Dehm
Molecular and Cellular Biology|March 3, 2004
SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitorsScott M Dehm, Traci L Hilton, Edith H Wang, et al.
Clinical and Translational Science|September 19, 2024
Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancerWeijie Zhang, Adam Lee, Lauren Lee, et al.
Cancer Research|October 19, 2007
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cellsScott M Dehm, Kevin M Regan, Lucy J Schmidt, et al.
Cancer Research|November 3, 2007
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancerHannelore V Heemers, Kevin M Regan, Scott M Dehm, et al.
Endocrine-Related Cancer|May 27, 2014
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancerKathryn E Ware, Mariano A Garcia-Blanco, Andrew J Armstrong, et al.
Cancer Research|January 21, 2011
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progressionYingming Li, Majid Alsagabi, Danhua Fan, et al.
Cancer Research|July 3, 2008
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistanceScott M Dehm, Lucy J Schmidt, Hannelore V Heemers, et al.
The Prostate|August 30, 2008
Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisKristin A Raclaw, Hannelore V Heemers, Emily M Kidd, et al.
American Journal of Clinical and Experimental Urology|September 15, 2020
Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in <i>TP53</i>, <i>PTEN</i> and <i>RB1</i> on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancerAllison P Watson, Ashraf Shabaneh, Jinhua Wang, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
The Journal of Steroid Biochemistry and Molecular Biology|April 19, 2024
Androgen receptor and estrogen receptor variants in prostate and breast cancersJosé C Valentín López, Carol A Lange, Scott M Dehm
Molecular and Cellular Biology|March 3, 2004
SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitorsScott M Dehm, Traci L Hilton, Edith H Wang, et al.
Clinical and Translational Science|September 19, 2024
Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancerWeijie Zhang, Adam Lee, Lauren Lee, et al.
Cancer Research|October 19, 2007
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cellsScott M Dehm, Kevin M Regan, Lucy J Schmidt, et al.
Cancer Research|November 3, 2007
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancerHannelore V Heemers, Kevin M Regan, Scott M Dehm, et al.
Endocrine-Related Cancer|May 27, 2014
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancerKathryn E Ware, Mariano A Garcia-Blanco, Andrew J Armstrong, et al.
Cancer Research|January 21, 2011
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progressionYingming Li, Majid Alsagabi, Danhua Fan, et al.
Cancer Research|July 3, 2008
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistanceScott M Dehm, Lucy J Schmidt, Hannelore V Heemers, et al.
The Prostate|August 30, 2008
Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisKristin A Raclaw, Hannelore V Heemers, Emily M Kidd, et al.
American Journal of Clinical and Experimental Urology|September 15, 2020
Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in <i>TP53</i>, <i>PTEN</i> and <i>RB1</i> on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancerAllison P Watson, Ashraf Shabaneh, Jinhua Wang, et al.
Pageof 13